Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial
The tetravalent dengue vaccine (CYD-TDV) is approved for use as a 3-dose series for the prevention of dengue in seropositive individuals ≥9 years. A randomized, placebo-controlled, phase II study of a booster dose of CYD-TDV in individuals who completed the 3-dose schedule >5 years previously (NC...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2021-07-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2020.1861875 |
| _version_ | 1797677186896887808 |
|---|---|
| author | Juliana Park Sophia Archuleta May-Lin Helen Oh Lynette Pei-Chi Shek Hao Wang Matthew Bonaparte Carina Frago Alain Bouckenooghe Frederique Jantet-Blaudez Sarah Begue Sophie Gimenez-Fourage Anke Pagnon |
| author_facet | Juliana Park Sophia Archuleta May-Lin Helen Oh Lynette Pei-Chi Shek Hao Wang Matthew Bonaparte Carina Frago Alain Bouckenooghe Frederique Jantet-Blaudez Sarah Begue Sophie Gimenez-Fourage Anke Pagnon |
| author_sort | Juliana Park |
| collection | DOAJ |
| description | The tetravalent dengue vaccine (CYD-TDV) is approved for use as a 3-dose series for the prevention of dengue in seropositive individuals ≥9 years. A randomized, placebo-controlled, phase II study of a booster dose of CYD-TDV in individuals who completed the 3-dose schedule >5 years previously (NCT02824198), demonstrated that a booster restored neutralizing antibody titers to post-dose 3 levels. We present additional immunogenicity assessments up to 24 months post-booster, and B- and T-cell responses in a participant subset. Participants aged 9–45 years that had received all three doses of CYD-TDV were randomized 3:1 to receive a booster dose of CYD-TDV (n = 89) or placebo (n = 29). Neutralizing antibody levels at Months 1, 6, 12, and 24 post-booster were assessed by plaque reduction neutralization test. In a subset, B-cell responses were assessed by a fluorescent immunospot assay, and T-cells analyzed by flow cytometry at Days 0, 7, 12, Months 1 and 12. We observed an increase of antibody titers Month 1 post-booster, then a gradual decline to Month 24. In the CYD-TDV booster group, an increase in plasmablasts was seen at Day 7 declining by Day 14, an increase in memory B-cells was observed at Day 28 with no persistence at Month 12. CYD-TDV booster recalled a CD8+ T-cell response, dominated by IFN-γ secretion, which decreased 12 months post-booster. This study showed a short-term increase in antibody titers and then gradual decrease following CYD-TDV booster injection >5 years after primary immunization, and the presence of memory B-cells activated following the booster, but with low persistence. |
| first_indexed | 2024-03-11T22:41:24Z |
| format | Article |
| id | doaj.art-01e9265349dd42e8983c677b9b6022e8 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T22:41:24Z |
| publishDate | 2021-07-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-01e9265349dd42e8983c677b9b6022e82023-09-22T08:51:53ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2021-07-011772107211610.1080/21645515.2020.18618751861875Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trialJuliana Park0Sophia Archuleta1May-Lin Helen Oh2Lynette Pei-Chi Shek3Hao Wang4Matthew Bonaparte5Carina Frago6Alain Bouckenooghe7Frederique Jantet-Blaudez8Sarah Begue9Sophie Gimenez-Fourage10Anke Pagnon11Sanofi PasteurNational University Hospital, National University Health SystemChangi General HospitalNational University of SingaporeSanofiSanofi PasteurSanofi PasteurSanofi PasteurSanofi PasteurSanofi PasteurSanofi PasteurSanofi PasteurThe tetravalent dengue vaccine (CYD-TDV) is approved for use as a 3-dose series for the prevention of dengue in seropositive individuals ≥9 years. A randomized, placebo-controlled, phase II study of a booster dose of CYD-TDV in individuals who completed the 3-dose schedule >5 years previously (NCT02824198), demonstrated that a booster restored neutralizing antibody titers to post-dose 3 levels. We present additional immunogenicity assessments up to 24 months post-booster, and B- and T-cell responses in a participant subset. Participants aged 9–45 years that had received all three doses of CYD-TDV were randomized 3:1 to receive a booster dose of CYD-TDV (n = 89) or placebo (n = 29). Neutralizing antibody levels at Months 1, 6, 12, and 24 post-booster were assessed by plaque reduction neutralization test. In a subset, B-cell responses were assessed by a fluorescent immunospot assay, and T-cells analyzed by flow cytometry at Days 0, 7, 12, Months 1 and 12. We observed an increase of antibody titers Month 1 post-booster, then a gradual decline to Month 24. In the CYD-TDV booster group, an increase in plasmablasts was seen at Day 7 declining by Day 14, an increase in memory B-cells was observed at Day 28 with no persistence at Month 12. CYD-TDV booster recalled a CD8+ T-cell response, dominated by IFN-γ secretion, which decreased 12 months post-booster. This study showed a short-term increase in antibody titers and then gradual decrease following CYD-TDV booster injection >5 years after primary immunization, and the presence of memory B-cells activated following the booster, but with low persistence.http://dx.doi.org/10.1080/21645515.2020.1861875cyd-tdvdengue vaccineb-cell responset-cell responsebooster vaccinelong-term follow-up |
| spellingShingle | Juliana Park Sophia Archuleta May-Lin Helen Oh Lynette Pei-Chi Shek Hao Wang Matthew Bonaparte Carina Frago Alain Bouckenooghe Frederique Jantet-Blaudez Sarah Begue Sophie Gimenez-Fourage Anke Pagnon Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial Human Vaccines & Immunotherapeutics cyd-tdv dengue vaccine b-cell response t-cell response booster vaccine long-term follow-up |
| title | Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial |
| title_full | Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial |
| title_fullStr | Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial |
| title_full_unstemmed | Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial |
| title_short | Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial |
| title_sort | humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5 years after completion of the primary series in singapore 2 year follow up of a randomized phase ii placebo controlled trial |
| topic | cyd-tdv dengue vaccine b-cell response t-cell response booster vaccine long-term follow-up |
| url | http://dx.doi.org/10.1080/21645515.2020.1861875 |
| work_keys_str_mv | AT julianapark humoralandcellularimmunogenicityandsafetyfollowingaboosterdoseofatetravalentdenguevaccine5yearsaftercompletionoftheprimaryseriesinsingapore2yearfollowupofarandomizedphaseiiplacebocontrolledtrial AT sophiaarchuleta humoralandcellularimmunogenicityandsafetyfollowingaboosterdoseofatetravalentdenguevaccine5yearsaftercompletionoftheprimaryseriesinsingapore2yearfollowupofarandomizedphaseiiplacebocontrolledtrial AT maylinhelenoh humoralandcellularimmunogenicityandsafetyfollowingaboosterdoseofatetravalentdenguevaccine5yearsaftercompletionoftheprimaryseriesinsingapore2yearfollowupofarandomizedphaseiiplacebocontrolledtrial AT lynettepeichishek humoralandcellularimmunogenicityandsafetyfollowingaboosterdoseofatetravalentdenguevaccine5yearsaftercompletionoftheprimaryseriesinsingapore2yearfollowupofarandomizedphaseiiplacebocontrolledtrial AT haowang humoralandcellularimmunogenicityandsafetyfollowingaboosterdoseofatetravalentdenguevaccine5yearsaftercompletionoftheprimaryseriesinsingapore2yearfollowupofarandomizedphaseiiplacebocontrolledtrial AT matthewbonaparte humoralandcellularimmunogenicityandsafetyfollowingaboosterdoseofatetravalentdenguevaccine5yearsaftercompletionoftheprimaryseriesinsingapore2yearfollowupofarandomizedphaseiiplacebocontrolledtrial AT carinafrago humoralandcellularimmunogenicityandsafetyfollowingaboosterdoseofatetravalentdenguevaccine5yearsaftercompletionoftheprimaryseriesinsingapore2yearfollowupofarandomizedphaseiiplacebocontrolledtrial AT alainbouckenooghe humoralandcellularimmunogenicityandsafetyfollowingaboosterdoseofatetravalentdenguevaccine5yearsaftercompletionoftheprimaryseriesinsingapore2yearfollowupofarandomizedphaseiiplacebocontrolledtrial AT frederiquejantetblaudez humoralandcellularimmunogenicityandsafetyfollowingaboosterdoseofatetravalentdenguevaccine5yearsaftercompletionoftheprimaryseriesinsingapore2yearfollowupofarandomizedphaseiiplacebocontrolledtrial AT sarahbegue humoralandcellularimmunogenicityandsafetyfollowingaboosterdoseofatetravalentdenguevaccine5yearsaftercompletionoftheprimaryseriesinsingapore2yearfollowupofarandomizedphaseiiplacebocontrolledtrial AT sophiegimenezfourage humoralandcellularimmunogenicityandsafetyfollowingaboosterdoseofatetravalentdenguevaccine5yearsaftercompletionoftheprimaryseriesinsingapore2yearfollowupofarandomizedphaseiiplacebocontrolledtrial AT ankepagnon humoralandcellularimmunogenicityandsafetyfollowingaboosterdoseofatetravalentdenguevaccine5yearsaftercompletionoftheprimaryseriesinsingapore2yearfollowupofarandomizedphaseiiplacebocontrolledtrial |